Question 1

What is Argenx?

Accepted Answer

Argenx is a Company.

Question 2

How often does Argenx appear in global news?

Accepted Answer

Tracked across 3 news events drawn from 19 articles.

Question 3

When was Argenx first tracked by Ergen?

Accepted Answer

First tracked on May 08, 2026.

Question 4

When was Argenx last mentioned in news?

Accepted Answer

Last active on Jul 27, 2026.

Question 5

What is Argenx's current news sentiment?

Accepted Answer

Aggregate sentiment score: 35 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Argenx in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 3 events.

Question 7

What is the most recent event involving Argenx?

Accepted Answer

FDA Expands VYVGART, VYVGART Hytrulo Label (May 08, 2026, 6 articles).

Question 8

How did the "FDA Expands VYVGART, VYVGART Hytrulo Label" event impact Argenx?

Accepted Answer

Argenx received United States — Food and Drug Administration approval for a label expansion of its drugs Efgartigimod alfa/hyaluronidase and Efgartigimod alfa/hyaluronidase, allowing them to be used for all adult patients with generalized myasthenia gravis (gMG). This expands the market for Argenx's key products.

Question 9

How did the "argenx half year 2026 results call" event impact Argenx?

Accepted Answer

Argenx is the company reporting its half year 2026 financial results and business update.

Question 10

How did the "argenx acquires Forte Biosciences" event impact Argenx?

Accepted Answer

Argenx is the acquirer, adding FB102 to its portfolio; the deal is funded from cash on hand and expected to close in Q3 2026.

Question 11

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.